A New Challenge for BCMA-Targeting Bispecific Antibodies

The Phase 1b clinical trial (NCT07332507), led by the National Cancer Institute (NCI), explores new possibilities for Teclistamab (Tecvayli), Johnson & Johnson's (JNJ) leading bispecific antibody. Teclistamab activates the patient's immune system by simultaneously binding to the B-cell maturation antigen (BCMA) on cancer cells and the CD3 receptor on T cells. This drug received accelerated approval from the U.S. Food and Drug Administration (FDA) as the first treatment for multiple myeloma in October 2022, and in March 2026, it received additional approval for use in combination with daratumumab. This trial is the first step in demonstrating whether Teclistamab can be effective in rare blood cancers beyond multiple myeloma.

Significant Unmet Medical Needs and the Current Status of Plasma Cell Neoplasm

Plasma cell neoplasm (PBL) is a very rare and aggressive subtype of non-Hodgkin lymphoma (NHL), primarily occurring in immunocompromised patients. Currently, there is no established standard of care, and treatments such as high-dose combination chemotherapy, including modified EPOCH regimens, are attempted. However, the historical median overall survival (OS) ranges from 6 to 32 months, indicating a very poor prognosis. Notably, these cancer cells are CD20-negative, a common target for B-cell lymphomas, which limits the use of existing targeted antibodies like rituximab. As a result, patients and clinicians eagerly await the emergence of new immunotherapies that target BCMA, which is expressed on the surface of these cancer cells.

Scientific Rationale and Design Features of the Phase 1b Trial

This Phase 1b trial is designed to evaluate the safety, tolerability, and optimal dosage of subcutaneous (SC) formulation Teclistamab in patients with relapsed or refractory plasma cell neoplasm. Researchers have focused on the fact that plasma cell neoplasm cells strongly express BCMA, similar to multiple myeloma cells. Indeed, case reports of patients who previously failed all standard treatments and received teclistamab off-label, achieving complete response (CR), have provided a solid scientific basis for this trial. The safety data obtained from this trial will be a crucial stepping stone for future, larger-scale confirmatory clinical trials.

Commercial and Clinical Value of Expanding Indications

The global market for non-Hodgkin lymphoma treatments is currently estimated at approximately $11 billion to $15 billion annually as of 2025/2026 and continues to grow. In 2025, Johnson & Johnson's Tecvayli recorded global sales of approximately $494 million, establishing its presence in the multiple myeloma market. If this trial is successful and the indication is expanded to plasma cell neoplasm, Tecvayli can secure a strong pricing power by dominating the rare disease market with little competition. From a corporate perspective, this means diversifying revenue streams by entering an untapped market, and for patients, it means the emergence of an innovative new drug that can be a lifeline.